Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
ViroVet, a Belgium-based livestock vaccine development spinout of KU Leuven, has raised more than €6m ($6.7m) of initial series B funding from investors including KU Leuven and its seed fund Gemma Frisius Fund. The deal was led by Seventure Partners with supporting contributions from Vives II, the university venture fund for Université catholique de Louvain, in addition to Flemish government-sponsored investment firm PMV and the latter’s venture fund Biotech Fund Flanders. Capricorn Partners and Agri Investment Fund filled out the round, proceeds of which will go toward product development. Founded in 2015, ViroVet has created a drug design technology intended to swiftly produce cost-effective vaccines for livestock animals. The approach originated from KU Leuven’s Rega Institute for Medical Research. ViroVet closed a €6.5m ($7.1m) series A round in October 2017 with a €1.5m ($1.8m) extension featuring Capricorn’s Sustainable Chemistry Fund. The first tranche was received in January 2017 from KU…
